Skip to main content
271 search results for:

JAK inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 18-10-2022 | Psoriatic arthritis | News | Article

    Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

    JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

  2. 04-06-2022 | EULAR 2022 | Conference coverage | Article

    Mixed results for MACE risk with JAK inhibitors in RA

    Two real-world studies looking at the risk for major cardiovascular events with JAK inhibitors versus TNF inhibitors in patients with rheumatoid arthritis show contradicting outcomes.

  3. 02-09-2021 | JAK inhibitors | News | Article
    Regulatory update

    FDA requires boxed warning updates for JAK inhibitors

    In addition, use of Janus kinase (JAK) inhibitors in the USA will be limited to certain patients with an inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors.

  4. 14-03-2022 | Giant cell arteritis | News | Article

    Phase 2 trial supports further investigation of JAK inhibitors for giant cell arteritis

    Findings from a proof-of-concept trial provide preliminary evidence to suggest that the JAK inhibitor baricitinib is well tolerated and may have efficacy for the treatment of relapsing giant cell arteritis.

  5. 14-01-2022 | Rheumatoid arthritis | News | Article

    JAK inhibitors may increase cholesterol in people with RA

    Treatment with any of the five JAK inhibitors approved for use in rheumatoid arthritis in the USA, Europe, or Japan may lead to an increase in serum cholesterol levels, suggest results of a systematic review and network meta-analysis.

  6. 08-02-2022 | Rheumatoid arthritis | News | Article
    News in brief

    Disease activity may be a risk factor for herpes zoster in RA patients taking JAK inhibitors

    Having several changes in targeted therapy and high disease activity are associated with an elevated risk for herpes zoster among people with rheumatoid arthritis receiving treatment with JAK inhibitors, indicate study findings published in RMD Open .

  7. 13-10-2021 | COVID-19 | News | Article
    News in brief

    High overall response rates to COVID-19 vaccination in people taking JAK inhibitors

    Most patients in the cohort were women (72%) with a diagnosis of RA (87%); the most commonly used JAK inhibitor was baricitinib (50%), followed by tofacitinib (27%) and upadacitinib (24%).

  8. 06-08-2021 | Rheumatoid arthritis | News | Article

    Study quantifies herpes zoster risk with JAK inhibitors, other DMARDs

    A comparison of different treatments for rheumatoid arthritis suggests that Janus kinase inhibitors are associated with the highest risk for herpes zoster, while some biologic DMARDs may also be linked to an increased risk.

  9. 21-02-2019 | Spondyloarthropathies | Feature | Article
    Updated June 2022

    Trials of JAK inhibitors in spondyloarthritis: A round-up

    medwireNews  rounds up the completed and ongoing clinical trials investigating JAK inhibitors in patients with spondyloarthritis.

  10. 03-02-2021 | Rheumatoid arthritis | News | Article

    Potential drug–drug interactions with JAK inhibitors may be going unrecognized

    In an analysis of a large US claims database, around 10% of patients with rheumatoid arthritis were prescribed a drug with the potential to interact with JAK inhibitors.

  11. 02-06-2021 | EULAR 2021 | Conference coverage | Article

    ​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients

    Study findings from the COVID-19 Global Rheumatology Alliance suggest that rheumatoid arthritis patients taking rituximab or JAK inhibitors are more likely to experience poor outcomes following SARS-CoV-2 infection than those taking TNF inhibitors.

  12. 07-06-2021 | EULAR 2021 | Conference coverage | Article

    Real-world studies point to similar effectiveness of JAK inhibitors and biologics

    Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.

  13. 16-11-2020 | JAK inhibitors | News | Article

    Meta-analysis queries VTE risk associated with JAK inhibitors in clinical trials

    “There remains considerable uncertainty about any link between JAK [inhibitor] therapy and VTE events,” say Mark Yates (King's College London, UK) and co-authors, noting that regulatory agencies in the USA and Europe have added warnings about VTE risk to the labels for approved JAK inhibitors “based upon a small number of randomised controlled trials” and long-term extension studies (LTEs).

  14. 25-01-2021 | COVID-19 | Podcast | Article

    Repurposing rheumatology drugs for COVID-19: JAK inhibitors

    Marwan Bukhari talks about the rationale behind investigating baricitinib and other JAK inhibitors for the treatment of COVID-19 and outlines the current efficacy data (10:42).

  15. 07-04-2021 | Rheumatoid arthritis | News | Article
    News in brief

    Network meta-analysis suggests comparable efficacy of JAK inhibitors in rheumatoid arthritis

    Findings from a network meta-analysis suggest that the efficacy profile of peficitinib is largely similar to that of other Janus kinase inhibitors in patients with rheumatoid arthritis.

  16. 28-01-2021 | COVID-19 | News | Article

    COVID-19 risk not increased in rheumatic disease patients taking biologics, JAK inhibitors

    In patients with chronic inflammatory arthritis, biologics and JAK inhibitors are associated with a reduced risk for confirmed or highly suspected COVID-19, but glucocorticoids are associated with an increased risk, according to a survey of patients in Northern Italy.

  17. 11-11-2020 | ACR 2020 | Conference coverage | Article

    ‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

    “The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

  18. 16-11-2020 | JAK inhibitors | Highlight | Teaser
    medwireNews top story

    Meta-analysis queries VTE risk associated with JAK inhibitors in clinical trials

    A meta-analysis of randomized controlled trials has found no significant association between Janus kinase inhibitor use and the risk for venous thromboembolism among patients with immune-mediated inflammatory diseases.

  19. 12-11-2020 | Rheumatoid arthritis | Highlight | Teaser
    ACR Convergence 2020 news

    ‘The Great Debate’: JAK inhibitors vs biologics following methotrexate failure in RA

    “The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

  20. 27-07-2020 | Rheumatoid arthritis | News | Article

    Similar RA outcomes with TNF inhibitors vs other biologics, JAK inhibitors

    medwireNews : Findings from two real-world studies suggest that rheumatoid arthritis patients treated with TNF inhibitors experience similar clinical outcomes and rates of discontinuation to those given other biologics or JAK inhibitors.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.